Meta-analysis · 2015
Tramadol for premature ejaculation: a systematic review and meta-analysis
Martyn-St James M, Cooper K, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, Frodsham L, Hood C (2015). Tramadol for premature ejaculation: a systematic review and meta-analysis. BMC Urology. doi:10.1186/1471-2490-15-6
Pooling 4 randomised trials (721 men), the opioid painkiller tramadol increased latency more than placebo, but trial quality was unclear, results varied widely and side effects were more common; addiction risk was not assessed.
Summary
Tramadol is a centrally acting painkiller with opioid effects that is sometimes prescribed off-label for premature ejaculation (PE). This systematic review searched MEDLINE and other databases to August 2014 for randomised controlled trials of tramadol in PE, with intravaginal ejaculatory latency time (IELT) as the main outcome.
Eight trials were included, most of unclear methodological quality because of limited reporting. Pooled data from four placebo-controlled trials (721 men) showed tramadol increased IELT significantly more than placebo over 8 to 12 weeks, but with high heterogeneity (I² = 74%). Single trials suggested tramadol outperformed on-demand paroxetine, sildenafil, lidocaine gel and behavioural therapy. Tramadol caused significantly more side effects than placebo or behavioural therapy, including erectile dysfunction, constipation, nausea, headache, sleepiness, dry mouth, dizziness, itching and vomiting.
Limitations
The trials varied in dose and duration, so no safe and effective minimum dose could be identified. None assessed addiction or breathing problems, and long-term safety in men with PE has not been studied.
What it means for you
Tramadol can delay ejaculation, but it is an opioid with a real risk of dependence and a long list of side effects, and the evidence behind its use for PE is weak. It is not a first-choice option, and it should only ever be taken under a doctor's supervision, never from an online seller or a friend.